Finance

Beta
Lists
MIST:NASDAQ
Milestone Pharmaceuticals Inc
$1.32
0.00%
(0.00) 1D
$1.36
+3.03% (+0.040)
After hours
Closed: Jul 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MIST...
Open
$1.32
High
$1.38
Low
$1.29
Mkt. cap
164.34M
Avg. vol.
1.36M
Volume
1.05M
52-wk high
$3.06
52-wk low
$1.00
EPS
-$0.68
Beta
0.97
Shares outstanding
124.50M
No. of employees
38
Open
$1.32
High
$1.38
Low
$1.29
Mkt. cap
164.34M
Avg. vol.
1.36M
Volume
1.05M
52-wk high
$3.06
52-wk low
$1.00
EPS
-$0.68
Beta
0.97
Shares outstanding
124.50M
No. of employees
38
News stories
From sources across the web
About Milestone Pharmaceuticals Inc
CEO-
Employees38
Founded2003
Headquarters-
SectorPharmaceutical industry
Websitemilestonepharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to MIST in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MIST in the last 3 months.
Highest
Current $1.32
$8.00 (+506.06%)
Average
$7.25 (+449.24%)
Lowest
$6.00 (+354.55%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Maintained
$8.00
+506.1%
05/26/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$7.00
+430.3%
05/14/2026
Ritu Baral
TD Cowen
Buy
Maintained
$8.00
+506.1%
05/13/2026
Unknown Analyst
Raymond James
Buy
Initiated
$6.00
+354.5%
04/09/2026
Tiago Fauth
Raymond James
Buy
Initiated
$6.00
+354.5%
04/09/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$8.00
+506.1%
12/16/2025
Last report
May 13, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.20 / $0.19
-206.67%miss
Revenue / Est. (USD)
238.00K / 25.17M
-99.05%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
1.55M
238.00K
Cost of goods sold
-
-
-
14.00K
Cost of revenue
-
-
-
14.00K
Research and development expenses
3.67M
3.94M
5.52M
3.25M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.86M
7.89M
13.28M
20.64M
Operating expense
12.53M
11.83M
18.80M
23.89M
Total operating expenses
12.53M
11.83M
18.80M
23.90M
Operating income
-12.53M
-11.83M
-17.26M
-23.66M
Other non operating income
-
-
-
-
EBT including unusual items
-12.97M
-11.92M
-17.41M
-26.07M
EBT excluding unusual items
-12.97M
-11.92M
-17.41M
-26.07M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.97M
-11.92M
-17.41M
-26.07M
Net profit margin
-
-
-1,126.07%
-10,952.10%
Earnings per share
-0.20
-0.12
-0.15
-0.20
Interest and investment income
516.00K
874.00K
833.00K
1.73M
Interest expense
-951.00K
-967.00K
-985.00K
-4.14M
Net interest expenses
-435.00K
-93.00K
-152.00K
-2.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.50M
-11.80M
-17.22M
-23.61M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer